drugset / Trial / NCT06513949
Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
Timeline
- Start
- 2025-08-15
- Primary completion
- 2027-09
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IC14 | Monoclonal antibody | — | Intravenous |